Mirati Therapeutics’ CVR Value In The Wake Of The Bristol Myers Acquisition (NASDAQ:MRTX)

gorodenkoff/iStock via Getty Images Mirati Therapeutics, Inc. (NASDAQ:MRTX) is at the forefront of oncological biotechnology. Its star product is adagrasib, commercially known as Krazati, a drug for treating KRAS G12C-mutated non-small cell lung cancer, which obtained accelerated approval from the FDA. This successful drug got the interest of Bristol-Myers Squibb (BMY) to acquire MRTX for…

Read More

CVR Partners, LP (UAN) Q3 2023 Earnings Call Transcript

CVR Partners, LP (NYSE:UAN) Q3 2023 Earnings Conference Call October 31, 2023 11:00 AM ET Company Participants Richard Roberts – Director, Financial Planning and Analysis and IR Mark Pytosh – CEO Dane Neumann – CFO Conference Call Participants Rob McGuire – Granite Research Operator Greetings, and welcome to the CVR Partners LP Third Quarter 2023…

Read More

CVR Energy: Strong Financials And Business Outlook Bring Bright Future (NYSE:CVI)

saoirse_2010/iStock via Getty Images Introduction CVR Energy (NYSE:CVI) is a company that has diversified its operations in the petroleum refining and marketing industry and the nitrogen fertilizer manufacturing industry; CVR Energy also produces and markets renewable diesel. In the petroleum refining segment, they refine and market transportation fuels. It is worth mentioning that CVR Energy…

Read More